Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Niraparib in Patients With Recurrent Glioma

NCT05297864 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT05297864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05297864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Niraparib in Patients With Recurrent Glioma
Lead sponsor
University of Oklahoma
Phase
Phase 2
Overall status
Terminated
Start date
June 9, 2022
Completion date
February 6, 2024
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent astrocytoma, recurrent glioblastoma, recurrent glioma, recurrent oligodendroglioma